2014’s Biotech IPO Class: Strong Starts
This article was originally published in Start Up
Fifteen biotechs from the IPO class of 2014 have more than doubled their values since their debuts. Those stand-outs drove the impressive overall performance of the 67 newly public biotechs in the cohort: overall, the average IPO in 2014 was up 52.2% as of February 27.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.